1,626 results on '"Maziarz, Richard T."'
Search Results
152. Bacterial Infections Post-Allogeneic Transplant Are Associated with Higher Relapse Related Mortality
153. Total Costs of Care and Complication Rates Among Patients with Hematologic Malignancies Who Receive Allogeneic Hematopoietic Cell Transplants in the US
154. Incidence and Outcomes from Transplant-Associated Thrombotic Microangiopathy in Allogeneic Pediatric Hematopoietic Stem Cell Transplant Recipients before and after the Introduction of Eculizumab: A Single Institution Experience from Oregon Health & Science University
155. Hospitalization and Healthcare Resource Use of Omidubicel Vs Umbilical Cord Blood (UCB) for Hematological Malignancies in a Global Randomized Phase III Clinical Trial Setting
156. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
157. Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison
158. Medicare Utilization and Cost Trends for CAR-T Cell Therapies in the Treatment of Large B-Cell Lymphoma
159. Chronic Graft-Versus-Host Disease, Non-Relapse Mortality and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A CIBMTR Analysis
160. Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma
161. Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
162. MSCs in Hematopoietic Cell Transplantation
163. Pregnancy after Hematopoietic Cell Transplantation: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR)
164. Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease
165. Informal caregiving in Hematopoietic Blood and Marrow Transplant patients
166. Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
167. Hospitalization and Healthcare Resource Use of Omidubicel Vs Cord Blood Transplantation for Hematological Malignancies in a Global Randomized Phase III Clinical Trial
168. Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas
169. Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium
170. A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
171. Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy
172. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study
173. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome
174. BMT CTN State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20(th) Year
175. Mesenchymal stromal cells: potential roles in graft-versus-host disease prophylaxis and treatment
176. Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease
177. Long-Term Sustained Disease Control in Patients With Mantle Cell Lymphoma With or Without Active Disease After Treatment With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning
178. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation
179. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia
180. Second Unrelated Donor Hematopoietic Cell Transplantation for Primary Graft Failure
181. Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia
182. Outcome of Transplantation for Myelofibrosis
183. Outcomes of Hematologic Malignancies after Unrelated Donor Hematopoietic Cell Transplantation According to Place of Residence
184. Control of an Outbreak of Human Parainfluenza Virus 3 in Hematopoietic Stem Cell Transplant Recipients
185. A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR
186. The evolving need for patient reported outcome data in determining choice of immune therapy treatment
187. Critical need for establishing value that justifies the current rising costs of cell and gene therapy
188. Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML
189. 508 - Second Autologous Stem Cell Transplant As Salvage in Multiple Myeloma – the Oregon Health and Science University Experience
190. 171 - Allogeneic Stem Cell Transplantation in Treatment Related and Secondary Acute Myeloid Leukemia and Myelodysplastic Syndrome: Ohsu Experience
191. 22 - Economic Burden and Health Resource Utilization Associated with Dsdna Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
192. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
193. Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation
194. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
195. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease
196. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
197. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements
198. Successful Stem Cell Remobilization Using Plerixafor (Mozobil) Plus Granulocyte Colony-Stimulating Factor in Patients with Non-Hodgkin Lymphoma: Results from the Plerixafor NHL Phase 3 Study Rescue Protocol
199. Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation
200. Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.